AGM - Chairman's and CEO's presentations

Attached is the Chairman's address together with the CEO's presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY), to be held at 4.00pm today.

An audio broadcast of the presentations may be heard from 4.30pm today on boardroomradio.com.

The presentation details are as follows:

- ***Annual General Meeting***
- ***Presented by Mr Peter Bartels, Chairman and Dr Jackie Fairley, CEO***
- ***15 November 2006***
- ***4.30pm***
- ***At http://www.brr.com.au/event/SPL/1305/17105/wmp/qt6aorkj5a***

To listen, simply click on the Windows Media Player, QuickTime or MP3 icon.

Additionally, the presentation can be accessed at www.boardroomradio.com where it will also be archived for future on-demand listening – if you miss the live presentation, you can log on later to hear the news.

About Starpharma:

Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel™ (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).

More broadly the company is actively exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families - a unique level of IP concentration among nanotechnology companies.

Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

Microbicides: A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.

Genital herpes: A recurrent, lifelong viral infection caused by the sexually transmitted herpes simplex virus type-2 (HSV-2). It is one of the most prevalent STIs, estimated to infect between 15% and 25% of male and female adults in developed countries. This figure is expected to rise to about 39% for males and 49% for females by 2025, unless effective preventive measures are found to reverse the trend. Herpes is estimated to affect one in six adults in America and new cases cost more than US$1.5 billion each year. The figures for Australia are similar with an estimated one in six adults suffering from genital herpes (3.4 million people).

HSV-2 infection has a marked effect on a sufferer's quality of life. The virus is highly contagious and women appear to be at greater risk of infection than men. HSV-2 infection can make people more susceptible to infection by HIV and increase the transmission rate of HIV. If transmitted from mother to baby, the disease has very serious consequences.

American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.

For further information:

Media	**Starpharma** www.starpharma.com	
Rebecca Wilson **Buchan Consulting** Tel: +61 2 9237 2800 Mob: +61 417 382 391 rwilson@bcg.com.au	**Dr Jackie Fairley** Chief Executive Officer +61 3 8532 2704	**Ben Rogers** Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com

Chairman's Address

Annual General Meeting

of

Starpharma Holdings Limited, 15 November, 2006

Welcome to the Starpharma AGM for fiscal year 2005-2006.

When I was asked to give a talk on leadership a few years ago, one theme that I developed at the time was the ability of leaders to use change to their advantage.

Although I was directing my comments to individuals at the time, my words could just have easily been targeted to corporate entities.

Starpharma is not averse to change. If anything, we embrace change at every opportunity and recognise this as an important process in evolving and growing a business.

There have been some outstanding recent examples of strategic change that I believe have strengthened our business globally.

One of them was the appointment of Jackie Fairley to CEO. When our CEO of 10 years, John Raff, decided to retire, a succession plan was required. Jackie played a major role in that plan. She settled in as chief operating officer and worked with John until the time was right for him to step down.

It was almost a question of 'when is a change not a change?' John's departure and Jackie's appointment took place as a seamless transition and never looked like shaking the unquestionable stability of the company.

Happily, John's influence will continue to guide Starpharma's business as he remains on the Board as deputy chair. I'd like to take the opportunity to thank him for a decade of leadership and commitment to Starpharma – the successful company you see today is in many ways a testament to him.

The second change occurred last month, outside the reporting period of this AGM, but very much worthy of mention when we acquired US company Dendritic Nanotechnologies, or DNT.

You may remember that Starpharma was a Pooled Development Fund when DNT was established. This limited our ability to make offshore investments, and as a result we relinquished control of DNT.

That situation has now changed. DNT is once again a wholly owned subsidiary of Starpharma and for our part; we have acquired a well-known entity and consolidated our IP position in the dendrimer field.

With the DNT acquisition, Starpharma realises a number of important benefits – access to revenue from product sales, an impressive portfolio of IP, new areas of dendrimer application and a new major shareholder – the Dow Chemical Company.

Importantly, the acquisition has also given us a clear passage to expand Starpharma in the US. Jackie Fairley and I have spent much of last month investigating ways to fast track our profile there.

We have previously foreshadowed a desire of adding a US based director to the board, and following the acquisition of DNT we've invited the former CEO of a major US corporate to become a director of Starpharma. We expect to be able to make an announcement confirming that appointment in the near future.

In summary, we see the acquisition of DNT as a company-changing event that will firm the future of Starpharma with a much expanded product portfolio and access to the US capital markets.

This was not the only IP-strengthening activity that took place during the year. We undertook another strategic buy-back of dendrimer IP that returned complete ownership of three patent families to Starpharma and removed technology licence arrangements established about 10 years ago when Starpharma was spun out of the Biomolecular Research Institute.

John Raff summed up our view of this IP buy back last October when he said "This is the right deal at the right time and it is very much in the interests of our shareholders."

Clearly, management's ability to accommodate, initiate and implement change is bearing very good outcomes.

On the clinical front, VivaGel has cleared a number of obstacles on an unfamiliar road to market and has gained considerable high-level support on the way. Whilst we recently announced an extension to regulatory approval milestones, the factors involved are less of an issue in the conduct of genital herpes trials. We are increasingly confident that the genital herpes indication has significant commercial potential and can provide a faster route to market without many of the challenging factors inherent in HIV trials.

Many experts in world health believe that the empowerment of women is essential if we are ever to stem the spread in the developed and developing worlds of sexually transmitted infections such as HIV and the virus that causes genital herpes.

One such expert and one of Australia's leading scientists, Sir Gustav Nossal, published a paper in which he strongly endorsed products such as VivaGel and singled out Starpharma for its steps toward preventing the spread of HIV and genital herpes, particularly through empowering women.

Our recent discovery that the active ingredient in VivaGel also acts as a potent contraceptive in rabbits has met with a very positive response from both our scientific and commercial staff. An additional, contraceptive, action can only increase the value of our microbicidal product.

It is extremely pleasing to confirm that clinical trials of VivaGel for HIV infection and genital herpes have already commenced in Australia and the US and will soon extend into Kenya.

For many biotechs, the only options for funding clinical development are commercial licensing deals or the financial markets.

While we approached the market to raise $15 million through a share placement and share purchase plan last November, we have been able to avoid 'selling the farm' as part of a commercial licensing deal.

The reason? Starpharma received 26 million Australian dollars from the National Institutes of Health in the US to develop VivaGel against the spread of HIV. We then received further funding for our genital herpes program.

A great thing about this substantial injection of funds is that it comes with no loss of product ownership, but has all the upside of short-term security for the project, validation of product concept and all-important access to US clinical expertise and influence.

VivaGel is the first microbicide to have received NIH funding for development against herpes and we are reasonably sure that it is the first microbicide with FDA investigational new drug status for prevention of herpes.

There is plenty of good news and also plenty of hard work ahead for the Board and management of Starpharma.

I'm confident that both are up to the challenges. I'd like to thank my fellow directors for their valuable counsel, and especially our retiring CEO John Raff, and our new CEO Jackie Fairley. I'd also like to thank all our staff for their continued hard work, absolute focus and commitment to the pursuit of excellence and to making Starpharma a clear leader in the global biotechnology industry.

I shall now bring to an end my fourth AGM presentation and hand over to Jackie for her first address as CEO.

Thank you.

Peter T Bartels
Chairman

Starpharma Holdings Limited
ASX:SPL
USOTC:SPHRY

AGM Presentation
15 November 2006

Dr Jackie Fairley – CEO

This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated, because of various important factors, risks and uncertainties. These include risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs and general economic uncertainty. Also, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

1. Key Achievements
2. Company Overview
3. VivaGel™
4. DNT Acquisition
5. Pipeline
6. Conclusion

1. Key Achievements

Key Achievements

✓	**HIV Funded: US$20.3M**	NIH funds VivaGel™ HIV development with non-dilutive funding
✓	**Genital Herpes Funded**	NIH funds VivaGel™ Genital Herpes Development
✓	**HIV Fast Tracked**	US regulator FDA designates VivaGel™ a fast track product
✓	**Herpes IND Cleared**	FDA clears VivaGel™ Genital Herpes IND
✓	**Contraceptive Activity**	VivaGel™ shown to be a potent contraceptive in animals
✓	**ADRs exceed 10%**	US uptake of ADRs exceeded 10% of SPL issued capital
✓	**A$15M Funds Raised**	Institutional and SPP capital raising
✓	**Patent Estate Expanded**	Substantial program of patent filing completed
✓	**Priostar™ Rolled Out**	DNT rolls out Priostar™ industrial dendrimer platform
✓	**Acquisition of DNT**	SPL acquires US company DNT
✓	**US Shareholding : c. 19%**	Dow becomes SPL's largest holder

The past 12 months has been a period of significant achievement for Starpharma

2. Company Overview

Company Overview

- World leader in the development of dendrimer nanotechnology products for pharmaceutical and life-sciences
- Lead product VivaGel™ is being developed (under IND) as a microbicide to prevent HIV and Genital Herpes
  - US$20.3m NIH funding to develop VivaGel™ for HIV
  - FDA Fast Track Status for HIV
  - VivaGel™ is the first microbicide with NIH funding support for Genital Herpes
- Two line extensions to VivaGel™ in development in addition to a broad portfolio of other dendrimer projects
- Wholly-owned US subsidiary (DNT Inc.)
  - Leader in the development of advanced dendritic polymers
  - Significant dendrimer IP portfolio

Starpharma Holdings Limited	
ASX Code	SPL
Level 1 ADR Code	SPHRY
Share Price (14/11/06)	51 c
12 Month High/Low	64 c / 35 c
Shares on Issue	167.8M
Market Capitalisation	~ $86M
Average Mthly Volume	4.5M shares
Cash on Hand (Oct 06)	$13.3M

Shareholder Composition



Starpharma is the global leader in dendrimer based nanotechnology

Company Structure



- 36 employees based in Melbourne, Australia
- Uses dendrimer technology to discover, develop and commercialise pharmaceuticals
- Lead development product VivaGel™ is a vaginal microbicide for the prevention of genital herpes and HIV
- Broad portfolio of other dendrimer projects including drug delivery, cancer and targeted diagnostics

- 16 employees based in Michigan, USA
- Leading developer and provider of advanced dendritic polymers
- Existing licensing agreements with established revenue streams for dendrimer technology
- Broad and comprehensive IP portfolio; approximately 180 patents/applications issued and pending

Financial Snapshot

- Starpharma is in a strong financial position:
  - A$13.3M in cash at Oct 06 (A$14.3M Jun 06)
  - 12 month burn to Oct 06 of A$6.6M (A$8.2M 05/06)
  - NIH and P3 Funding > A$30M
  - Loss for 05/06 down 3% to A$7.5M
  - Revenue[1] A$7.0M in 05/06, a A$5M increase over 04/05

[1] Post DNT transaction : additional revenue ~ A$1.25M pa

Cash on Hand



Revenue



ADR Program and US Shareholding

- Starparma's ADR program has been extremely successful since launch in January 2005
  - Growth of 137% in ADRs issued in the past 12 months
  - Average monthly growth of 7%
- Traded by major brokers including Merrill Lynch, Credit Lyonnais, Natexis Bleichroeder, and Pershing LLC
- ADR's exceeded 10% of SPL capital issued in October 2006
  - Currently at 9.3% following issue of shares for acquisition of DNT
- SPHRY compares favourably against other Australian biotech Level-1 ADR programmes
  - Most heavily traded by volume and price
- Active program initiated to build on US interest in SPL/SPHRY
  - US investors represent 19.5% of SPL total shareholding



Enhanced Pipeline: Balanced for Risk



3. VivaGel™

VivaGel™ packaged into pre-filled applicators.

VivaGel™ – Lead Product for Prevention of STIs

- VivaGel™ is a vaginal microbicide being developed to prevent sexually transmitted infections in women
  - Currently being developed under two INDs for the prevention of HIV and genital herpes
- Gel-based formulation with a nanotech active (SPL7013), delivered via an applicator
- Active ingredient inactivates HIV and HSV-2 (genital herpes) virus by binding with the virus preventing it attaching to the host
- Significant and growing recognition that microbicides offer the best alternative
  - "Prevention is better than cure"

HIV

- Major health burden in both developed and developing countries
- 39 million people living with HIV; every day 7,000 women are newly infected
- No cure - more than 50 HIV vaccines have failed and estimates are that an effective vaccine is many years away

Genital Herpes

- Recurrent, lifelong viral infection
- Estimated to infect between 15-25% of male and female adults in developed countries, growing to between 40-50% in the US by 2025
- Existing prevention methods have proven ineffective and developmental vaccines disappointing

VivaGel™ offers an attractive first line defence against the spread of HIV and genital herpes

VivaGel™ – Significant Achievements



- Successfully completed Phase 1 trial in Humans
- Receives A$26M non-dilutive NIH funding for development in HIV (without downstream commercial obligations)
- Granted FDA Fast Track Status for HIV
- The only microbicide funded by the NIH for Genital Herpes (clinical development, undisclosed sum)
- Exhibits a potent contraceptive effect in animal studies
- Further clinical trials underway Australia/USA; others to commence shortly in Kenya

VivaGel™ Market Update

- Two clinical trials underway in the USA and Australia (Kenyan site to commence shortly)
- Good progress with Scale-up and toxicology programs
- Due to HIV Microbicide trial issues with recruitment, and retention in trials VivaGel™ regulatory approval milestone revised from 2008 by 12-24 mo.
- Genital Herpes indications likely less impacted - still anticipated to be first to market for Genital Herpes
- Issues not applicable to contraception indication and condom coating opportunity
- Opportunities for mitigation being actively pursued: choice of trial site, trial design, sample size etc.
- Market Outlook continues to be very good and strengthening:
  - Genital Herpes prevalence in US women: 26%
  - 30-40% female college students would buy a microbicide, ~70% if contraceptive
  - US Opinion leaders calling for a national herpes prevention program
- Negligible impact on cumulative development costs; NIH funding not impacted

Commercial Opportunity for Microbicides

- **Large, addressable markets**
  - HIV primarily in developing countries
  - HSV-2 in both developing and developed countries
- **Increasing market support for products**
  - US government firmly committed to development of safe and effective microbicides
  - US opinion leaders now calling for National Herpes Control Program
- **Several industry surveys have confirmed strong consumer demand**
  - Over 20 million women in US would use a microbicide
  - 30-40% female US college students would buy a microbicide increasing to 70% with contraceptive properties
  - Strong market demand at 5x local condom price in various countries
  - Microbicide market estimates >$1.5Billion

Estimated Market for microbicides in *Developed* Countries

Market Penetration	Average Frequency of Use Per Annum		
	25x US$M	50x US$M	100x US$M
2.5%	365	730	1,460
5.0%	725	1,450	2,900
10.0%	1,450	2,900	5,800

Key assumptions

- *291m women of reproductive age (15-49) in developed countries*
- *Unit sale price circa US$2*
- *Usage rates according to published data*

"If I had a magic bullet to accelerate something it would be the microbicide…"

Bill Gates, July 2006

Source: World Bank; UNAIDs; EC AIDS survey; BCG analysis and various microbicide publications

4. DNT Acquisition

starpharma

DOW®

dnt™

DENDRITIC NANOTECHNOLOGIES INC

Significant Acquisition Benefits

1. Diversified Product Portfolio

- Marketed products, near-term revenues
- Diversified risk: pharma, life-science and industrial

2. Significant Development and Commercialisation Synergies

- Optimal leverage of internal resources including commercial, regulatory, scale-up and discovery
- Better value from expenditures

3. Extensive IP Portfolio: Leaders in the Field

- Enhanced competitive position and higher profile for commercial development

4. Increased US Presence

- Greater access and profile in the US nanotech sector
  - industry partners
  - financial markets
  - funding partners

5. Ongoing Dow Involvement

- The Dow Chemical Company (Dow) is Starpharma's largest shareholder
  - Enhances Starpharma's profile with industry and funding partners

6. Attractive Acquisition Terms

- Minimal dilution for Starpharma shareholders
- Simplifies structure and puts in place platform for creating significant additional shareholder value

Enhanced Portfolio



5. Pipeline



starpharma

Enhanced Pipeline: Balanced for Risk



Pipeline: Enhanced Near Term Opportunities

Marketed Dendrimer Products

- Existing product sales and licensed dendrimer royalty agreements
  - Stratus CS® : Cardiac marker diagnostic licensed to Dade Behring
  - SuperFect® : Gene transfection technology licensed to Qiagen
  - STARBURST® dendrimers commercially available

DADE BEHRING

QIAGEN

ALDRICH

Current Revenues

PrioFect™ siRNA transfection agents

- Transfection reagent market: $120M growing by 15-18% pa
- PrioFect™ siRNA Transfection Reagents provide:
  - Precise size control: allows optimisation according to cell type
  - Highly functionalised surface: allows targeting to specific cell types i.e. cell-specific delivery
  - Pharmaceutical Quality: Low toxicity

Estimated market entry: Early 2007

Materials Science / Industrial Applications

Sector	Discussions with…	Application
Oil	"Top 5" US Oil Company	Lubricant additives
Plastics	Large Automotive Components Manufacturer	Plastics additive
Manufacturing	Major Technology Company	Dental resins
	Multiple avenues of exploration	Adhesives
	"Top 5" European electronics manufacturer	Printed circuit board manufacturing
Pharmaceutical	Global Healthcare Company	Solublisation
Cosmetics	Cosmetic Company	Adhesive
Fine Chemicals	Major fine chemical manufacturer	Laboratory reagents
Resources	Water quality specialists	Water filtering/ remediation

Value capture horizon : 2007 / 08

6. Conclusion

Investment Highlights

- >US$26m* non-diluting funding from the NIH for VivaGel™; P3 funding from the Australian Government for lead development
- VivaGel™ - the only microbicide with NIH funding for genital herpes
- Significant commercial opportunities for microbicides
- Significant US shareholder base and profile:
  - Dow is the largest shareholder (8.6%)
  - c.20% shares held by US shareholders
  - Successful ADR program ~ 9.3% shares on issue
  - US subsidiary with marketed products and extensive commercial relationships
  - US based ex. CEO/Chairman of major corporate to join SPL Board shortly
- Diversified dendrimer product and application pipeline:
  - Marketed products offering near-term revenues
  - Diversified risk: pharma, life-science and industrial
- Comprehensive dendrimer IP portfolio for a broad spectrum of products and applications

Starpharma represents a significant value proposition given its pipeline, cash position and NIH support

** Two NIH grants: US$20.3m contract + US$5.4m grant (2004)*

Preview:
New website in preparation

www.starpharma.com



Further information: info@starpharma

Supplementary Material

Dendrimer Technology: Overview

Unique Characteristics of Dendrimers

- Precisely defined, synthetic macromolecules
- Precisely defined surface topology
- Can be designed to optimize potency, pharmacokinetics and localisation
- Different species can be heat stable or biodegradable
- High multivalent binding affinity

Commercial Applications of Dendrimers

- Key enabling nanoscale technology
- Diverse range of pharma, diagnostic & materials applications
- In the clinic – VivaGel™ (the first dendrimer IND)
- Scalable chemical manufacturing process with competitive COGs
- Well tolerated







VivaGel™ – Product Features and Performance

Product Offers Several Key Advantages	▪ Market research indicates microbicide gels will have good uptake ▪ Female controlled, discreet and convenient ▪ Compelling competitive advantages: efficacy; non-irritant; broad activity ▪ Contraceptive activity (in animals)
Excellent Clinical Results in Human and Primate Trials	▪ Human trials (IND): VivaGel™ is non-toxic and non-irritating ▪ Potent activity in relevant HIV strains in very tough primate trials ▪ Potent activity against herpes in animal trials ▪ Viruses appear not to develop resistance to VivaGel™
Excellent Drug Characteristics	▪ Lower risk development – Topical gel, external to body ▪ Affordable – Low manufacturing costs ▪ Excellent IP position ▪ Passes key FDA hurdle – Well defined chemical entity
Product Extensions	▪ Condom coating ▪ In combination (ComboGel)

VivaGel™ – Significant Advantages Over Competitors

	Competitor Category	Key Disadvantages	VivaGel™ Advantages
HSV -2	**VivaGel™ is the only microbicide with an FDA IND for genital herpes**		
HIV **Significant Advantages over Other Products in Development**	Surfactants/ Detergents	▪ Ulceration possible; potential incr. risk of HIV infection	▪ No surfactant properties; non-irritant; does not increase infection risk
	Sulphated carbohydrates	▪ Not active against clinical HIV strains	Highly active against all HIV strains tested
	Reverse Transcript. Inhibitors and other anti-viral drugs	▪ Drug resistance is an issue ▪ Primary mode of action requires infection process to have begun ▪ Not active against herpes	▪ Very high barrier to development of viral resistance ▪ Primary mode of action is prevention of virus attachment ▪ Potent activity against herpes
	Sulphated Polymers	▪ High cost of synthesis ▪ Poor characterisation of the drug substance likely to present regulatory issues	▪ Excellent drug characteristics: ▪ Low manufacturing costs ▪ Stable, well defined entity
	Acidity Control Agents	▪ Acidity control: sufficient protection as mono-therapy?	▪ Potent activity against HIV and HSV-2 in animal models; non-irritant

Pipeline Management



Combination of "in house", partnered and 3rd party development maximises IP exploitation

Partners

starpharma

Industry Collaborators

Research/Uni. Collaborators